Cargando…

Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model

Anthrax is primarily recognized as an affliction of herbivores with incubation period ranging from three to five days post-infection. Currently, the Sterne live-spore vaccine is the only vaccine approved for control of the disease in susceptible animals. While largely effective, the Sterne vaccine h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndumnego, Okechukwu C., Koehler, Susanne M., Crafford, Jannie E., Beyer, Wolfgang, van Heerden, Henriette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240085/
https://www.ncbi.nlm.nih.gov/pubmed/30446695
http://dx.doi.org/10.1038/s41598-018-35382-8
_version_ 1783371569511268352
author Ndumnego, Okechukwu C.
Koehler, Susanne M.
Crafford, Jannie E.
Beyer, Wolfgang
van Heerden, Henriette
author_facet Ndumnego, Okechukwu C.
Koehler, Susanne M.
Crafford, Jannie E.
Beyer, Wolfgang
van Heerden, Henriette
author_sort Ndumnego, Okechukwu C.
collection PubMed
description Anthrax is primarily recognized as an affliction of herbivores with incubation period ranging from three to five days post-infection. Currently, the Sterne live-spore vaccine is the only vaccine approved for control of the disease in susceptible animals. While largely effective, the Sterne vaccine has several problems including adverse reactions in sensitive species, ineffectiveness in active outbreaks and incompatibility with antibiotics. These can be surmounted with the advent of recombinant peptides (non-living) next generation vaccines. The candidate vaccine antigens comprised of recombinant protective antigen (PA), spore-specific antigen (bacillus collagen-like protein of anthracis, BclA) and formaldehyde inactivated spores (FIS). Presently, little information exists on the protectivity of these novel vaccine candidates in susceptible ruminants. Thus, this study sought to assess the immunogenicity of these vaccine candidates in goats and evaluate their protectivity using an in vivo mouse model. Goats receiving a combination of PA, BclA and FIS yielded the highest antibody and toxin neutralizing titres compared to recombinant peptides alone. This was also reflected in the passive immunization experiment whereby mice receiving immune sera from goats vaccinated with the antigen combination had higher survival post-challenge. In conclusion, the current data indicate promising potential for further development of non-living anthrax vaccines in ruminants.
format Online
Article
Text
id pubmed-6240085
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62400852018-11-26 Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model Ndumnego, Okechukwu C. Koehler, Susanne M. Crafford, Jannie E. Beyer, Wolfgang van Heerden, Henriette Sci Rep Article Anthrax is primarily recognized as an affliction of herbivores with incubation period ranging from three to five days post-infection. Currently, the Sterne live-spore vaccine is the only vaccine approved for control of the disease in susceptible animals. While largely effective, the Sterne vaccine has several problems including adverse reactions in sensitive species, ineffectiveness in active outbreaks and incompatibility with antibiotics. These can be surmounted with the advent of recombinant peptides (non-living) next generation vaccines. The candidate vaccine antigens comprised of recombinant protective antigen (PA), spore-specific antigen (bacillus collagen-like protein of anthracis, BclA) and formaldehyde inactivated spores (FIS). Presently, little information exists on the protectivity of these novel vaccine candidates in susceptible ruminants. Thus, this study sought to assess the immunogenicity of these vaccine candidates in goats and evaluate their protectivity using an in vivo mouse model. Goats receiving a combination of PA, BclA and FIS yielded the highest antibody and toxin neutralizing titres compared to recombinant peptides alone. This was also reflected in the passive immunization experiment whereby mice receiving immune sera from goats vaccinated with the antigen combination had higher survival post-challenge. In conclusion, the current data indicate promising potential for further development of non-living anthrax vaccines in ruminants. Nature Publishing Group UK 2018-11-16 /pmc/articles/PMC6240085/ /pubmed/30446695 http://dx.doi.org/10.1038/s41598-018-35382-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ndumnego, Okechukwu C.
Koehler, Susanne M.
Crafford, Jannie E.
Beyer, Wolfgang
van Heerden, Henriette
Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title_full Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title_fullStr Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title_full_unstemmed Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title_short Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
title_sort immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in a/j mouse model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240085/
https://www.ncbi.nlm.nih.gov/pubmed/30446695
http://dx.doi.org/10.1038/s41598-018-35382-8
work_keys_str_mv AT ndumnegookechukwuc immunogenicityofanthraxrecombinantpeptidesandkilledsporesingoatsandprotectiveefficacyofimmuneserainajmousemodel
AT koehlersusannem immunogenicityofanthraxrecombinantpeptidesandkilledsporesingoatsandprotectiveefficacyofimmuneserainajmousemodel
AT craffordjanniee immunogenicityofanthraxrecombinantpeptidesandkilledsporesingoatsandprotectiveefficacyofimmuneserainajmousemodel
AT beyerwolfgang immunogenicityofanthraxrecombinantpeptidesandkilledsporesingoatsandprotectiveefficacyofimmuneserainajmousemodel
AT vanheerdenhenriette immunogenicityofanthraxrecombinantpeptidesandkilledsporesingoatsandprotectiveefficacyofimmuneserainajmousemodel